ライフサイエンスコーパス: concurrent treatment

1 n epithelial cells remain unaffected by this concurrent treatment.

2 site, and having nonadvanced disease without concurrent treatment.

3 viduals, there is growing advocacy for their concurrent treatment.

4 Concurrent treatment appeared to be well tolerated and e

5 and four (2.9%) of 137 patients who received concurrent treatment; by week 24, it had dropped below t

6 tosis assay, whereas the reverse sequence or concurrent treatment did not potentiate apoptosis.

7 f 142 (54.2%, 95% CI 45.7-62.6) who received concurrent treatment (difference 2.3%, 95% CI -9.3 to 13

8 ature of treatment during the run-in period, concurrent treatment during the treatment period, and in

9 In a concurrent treatment efficacy study, the target maintena

10 tion and function between patients receiving concurrent treatment for HIV-tuberculosis coinfection an

11 weeks, while those randomly assigned to the concurrent treatment group received paclitaxel and trast

12 18 patients completed at least one course of concurrent treatment (median, two courses; range, one to

13 Concurrent treatment of B16F10 tumor-bearing mice with T

14 epression and suggest a new strategy for the concurrent treatment of both conditions via modulation o

15 Concurrent treatment of cells with arsenite and the radi

16 Concurrent treatment of ketorolac or diclofenac with cid

17 resent study, we have examined the effect of concurrent treatment of OVCA 420 human ovarian cancer ce

18 oma-secreted protein-2 (Na-ASP-2), following concurrent treatment of schoolchildren coinfected with S

19 Concurrent treatment of the RPE65-immunized rats with B.

20 eved in this patient population suggest that concurrent treatment with anticonvulsants and dexamethas

21 h and ototoxic injury that can be reduced by concurrent treatment with caspase inhibitors in vitro.

22 erved over the past 3 decades have been from concurrent treatment with chemotherapy and radiotherapy

23 d poorly to cisplatin, but were sensitive to concurrent treatment with cisplatin and EGFR or Stat3 in

24 purpose of this study was to assess whether concurrent treatment with GCs (prednisolone) and risedro

25 Concurrent treatment with GCs and risedronate prevented

26 h artery calcification has been inhibited by concurrent treatment with ibandronate or osteoprotegerin

27 Concurrent treatment with immune modifier agents and/or

28 Six of the 7 patients underwent concurrent treatment with immune modifier drugs.

29 lity and that this effect may be enhanced by concurrent treatment with IVIG.

30 have utilized extreme hypoxia (0.5% O2) and concurrent treatment with metal carcinogen (nickel) to e

31 The cytotoxicity was blocked by concurrent treatment with MK-801 or by two tetrahydroiso

32 Many patients with epilepsy require concurrent treatment with more than one antiepileptic dr

33 We argue that these increases are related to concurrent treatment with neuroleptics rather than a dir

34 of BCNU polymers against malignant gliomas, concurrent treatment with O6-BG may provide an important

35 te-to-severe ulcerative colitis who received concurrent treatment with oral corticosteroids or immuno

36 Concurrent treatment with PD 98059 and CWF produced addi

37 Moreover, concurrent treatment with PDGF and insulin did not dimin

38 received one prior regimen as neoadjuvant or concurrent treatment with radiation.

39 cDDP-mediated tumor cell kill as compared to concurrent treatment with Ro23-7553 and cDDP or cDDP alo

40 In the present study, concurrent treatment with robotic step training and a se

41 of MEK inhibitor-insensitive CRC cell lines, concurrent treatment with selumetinib did not provide ad

42 Conversely, concurrent treatment with SN-38 and UCN-01 resulted in S

43 ering RNA-mediated knockdown of RelA/p65, or concurrent treatment with SP600125, indicating a require

44 Concurrent treatment with temozolomide and radiotherapy

45 ncrease in bone resorption activity and that concurrent treatment with the 40-mg dose of SB 242784 re

46 both of these effects were fully blocked by concurrent treatment with the CRF receptor antagonist D-

47 In vitro, concurrent treatment with the estrogen receptor antagoni

48 obilization of TRPC6 channels was blocked by concurrent treatment with the NMDA antagonist MK-801 and

49 TMS and in Apoe(-/-)/Cyp1b1(-/-) mice and by concurrent treatment with the superoxide scavenger 4-hyd

50 degree of secondary hyperparathyroidism and concurrent treatment with vitamin D.